Peer-Reviewed Publication
Sci Rep2024;14(1):12680.June 20, 2024Journal Article
In vivo brain estrogen receptor density by neuroendocrine aging and relationships with cognition and symptomatology.
Lisa Mosconi1,2, Matilde Nerattini3,4, Dawn C Matthews5, Steven Jett3, Caroline Andy6, Schantel Williams3, Camila Boneu Yepez3, Camila Zarate3, Caroline Carlton3, Francesca Fauci3, Trisha Ajila3, Silky Pahlajani3,7, Randolph Andrews5, Alberto Pupi4, Douglas Ballon7, James Kelly7, Joseph R Osborne7, Sadek Nehmeh7, Matthew Fink3, Valentina Berti4, Jonathan P Dyke, Roberta Diaz Brinton8
1Department of Neurology, Weill Cornell Medicine, 402 East 70th Street, LH-404, New York, NY, 10021, USA. lim2035@med.cornell.edu.
2Department of Radiology, Weill Cornell Medicine, New York, NY, USA. lim2035@med.cornell.edu.
3Department of Neurology, Weill Cornell Medicine, 402 East 70th Street, LH-404, New York, NY, 10021, USA.
4Nuclear Medicine Unit, Department of Biomedical Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
5ADM Diagnostics, Grayslake, IL, USA.
6Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
7Department of Radiology, Weill Cornell Medicine, New York, NY, USA.
8Department of Pharmacology and Neurology, University of Arizona, Tucson, AZ, USA.
Abstract
17β-estradiol, the most biologically active estrogen, exerts wide-ranging effects in brain through its action on estrogen receptors (ERs), influencing higher-order cognitive function and neurobiological aging. However, our knowledge of ER expression and regulation by neuroendocrine aging in the living human brain is limited. This in vivo brain 18F-fluoroestradiol (18F-FES) Positron Emission Tomogr…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans